US · WST
West Pharmaceutical Services, Inc.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Exton, PA 19341-0645
- Website
- westpharma.com
Price · as of 2025-12-31
$300.68
Market cap 18.32B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $203.82 | -32.21% |
| Intrinsic Value(DCF) | $108.37 | -63.96% |
| Graham-Dodd Method(GD) | $63.85 | -78.76% |
| Graham Formula(GF) | $96.02 | -68.07% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $18.97 | $54.17 | $0.00 | $8.50 | $17.68 |
| 2012 | $28.93 | $45.21 | $1.86 | $9.51 | $16.69 |
| 2013 | $44.00 | $47.15 | $1.83 | $13.67 | $25.46 |
| 2014 | $51.76 | $49.51 | $2.59 | $14.77 | $21.43 |
| 2015 | $62.68 | $49.53 | $1.47 | $12.66 | $8.76 |
| 2016 | $78.84 | $62.93 | $2.43 | $16.31 | $30.92 |
| 2017 | $89.70 | $67.09 | $0.77 | $18.12 | $28.28 |
| 2018 | $99.55 | $75.28 | $0.00 | $22.92 | $42.58 |
| 2019 | $147.66 | $98.48 | $3.43 | $26.99 | $49.67 |
| 2020 | $270.65 | $173.99 | $52.13 | $37.25 | $111.58 |
| 2021 | $359.30 | $248.09 | $352.43 | $64.09 | $342.89 |
| 2022 | $311.99 | $208.02 | $186.60 | $63.11 | $79.09 |
| 2023 | $356.80 | $220.49 | $74.13 | $65.74 | $81.74 |
| 2024 | $230.66 | $163.29 | $9.71 | $56.89 | $41.96 |
| 2025 | $251.25 | $203.82 | $13.38 | $63.85 | $96.02 |
AI valuation
Our deep-learning model estimates West Pharmaceutical Services, Inc.'s (WST) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $203.82
- Current price
- $300.68
- AI upside
- -32.21%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$108.37
-63.96% upside
Graham-Dodd
$63.85
-78.76% upside
Graham Formula
$96.02
-68.07% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| WST | West Pharmaceutical Servi… | $300.68 | 18.32B | -32% | -64% | -79% | -68% | 36.79 | 5.72 | 5.91 | 24.59 | 2237.77 | 5.94 | 35.89% | 20.09% | 16.06% | 16.85% | 18.68% | 12.48% | 0.13 | 1029.00 | 3.02 | 2.09 | -0.52 | 164.00% | 626.00% | 6965.00% | 2.58% | 1.15 | 17.68% | 0.34% | 12.40% | 2.15% | 28.82 | 37.94 | 5.79 | 12.97 |
| COO | The Cooper Companies, Inc… | $83.67 | 16.63B | -16% | -60% | -63% | -71% | 44.52 | 2.03 | 4.08 | 18.38 | — | 5.96 | 60.67% | 16.69% | 9.16% | 4.59% | 4.21% | 3.03% | 0.34 | 6.83 | 1.89 | 0.84 | 2.54 | -459.00% | 506.00% | 5054.00% | 2.60% | 0.72 | 4.04% | 0.00% | 0.00% | 1.74% | 28.35 | 44.65 | 4.73 | 3.88 |
| DGX | Quest Diagnostics Incorpo… | $211.91 | 23.57B | -3% | -58% | — | -18% | 22.31 | 3.25 | 2.11 | 13.60 | 161.86 | -6.84 | 31.93% | 14.53% | 8.99% | 15.00% | 9.14% | 6.46% | 0.96 | 6.07 | 1.04 | 0.80 | 2.96 | 1378.00% | 1178.00% | 4950.00% | 5.82% | 0.83 | 10.07% | 1.51% | 33.70% | 3.61% | 18.61 | 21.95 | 2.70 | 3.44 |
| HOLX | Hologic, Inc. | $75.36 | 16.82B | +9% | -53% | -75% | -67% | 30.11 | 3.37 | 4.15 | 17.05 | — | 20.82 | 61.00% | 17.42% | 13.80% | 11.12% | 10.86% | 6.23% | 0.52 | 16.73 | 3.75 | 2.87 | 0.65 | -2500.00% | 174.00% | -1964.00% | 5.40% | 1.08 | 16.84% | 0.00% | 0.00% | 4.42% | 24.44 | 18.97 | 4.26 | 4.18 |
| ILMN | Illumina, Inc. | $134.46 | 20.56B | -15% | -56% | -72% | -69% | 23.92 | 7.47 | 4.68 | 14.59 | — | 14.52 | 66.49% | 19.92% | 19.58% | 33.36% | 18.25% | 13.13% | 0.94 | 8.65 | 2.08 | 1.57 | 0.78 | -17074.00% | -69.00% | 3131.00% | 4.58% | 0.68 | 25.10% | 0.00% | 0.00% | 5.42% | 24.57 | 22.83 | 4.89 | 4.42 |
| INCY | Incyte Corporation | $101.27 | 20.15B | +47% | +302% | -42% | +85% | 15.18 | 3.78 | 3.80 | 9.10 | 0.36 | 3.97 | 91.47% | 26.12% | 25.03% | 29.87% | 69.44% | 20.75% | 0.01 | 553.03 | 3.32 | 3.04 | -1.72 | 417333.00% | 2122.00% | 44387.00% | 6.94% | 0.93 | 90.63% | 0.00% | 0.00% | 7.19% | 11.93 | 11.82 | 3.12 | 8.52 |
| LH | Labcorp Holdings Inc. | $289.12 | 23.97B | -28% | -60% | -89% | -45% | 27.16 | 2.77 | 1.71 | 15.16 | 148.18 | -13.50 | 26.75% | 10.87% | 6.28% | 10.53% | 8.26% | 4.77% | 0.84 | 6.77 | 1.42 | 0.99 | 3.31 | 1833.00% | 725.00% | 1005.00% | 5.06% | 0.58 | 8.29% | 1.01% | 27.40% | 2.90% | 20.12 | 25.30 | 2.19 | 3.23 |
| MEDP | Medpace Holdings, Inc. | $451.76 | 12.82B | -29% | +273% | -84% | -6% | 29.25 | 28.75 | 5.22 | 22.70 | 139.42 | -55.74 | 30.06% | 21.14% | 17.83% | 70.23% | 171.74% | 22.13% | 0.55 | — | 0.74 | 0.67 | -0.43 | 2098.00% | 1997.00% | 1915.00% | 5.17% | 0.53 | 263.19% | 0.00% | 0.00% | 6.95% | 24.21 | 18.99 | 5.12 | 6.85 |
| STE | STERIS plc | $252.35 | 24.77B | -33% | -62% | -91% | -65% | 38.71 | 3.61 | 4.37 | 19.05 | 61.70 | 36.50 | 44.01% | 15.87% | 11.26% | 9.55% | 7.35% | 5.81% | 0.33 | 10.05 | 1.96 | 1.19 | 1.49 | 6273.00% | 624.00% | 2693.00% | 3.26% | 1.12 | 8.59% | 0.92% | 35.70% | 6.61% | 29.86 | 33.26 | 4.74 | 5.33 |
| WAT | Waters Corporation | $319.38 | 19.01B | -23% | -58% | -77% | -50% | 28.45 | 7.14 | 5.78 | 18.88 | 6094.04 | 27.58 | 57.77% | 28.22% | 20.30% | 29.28% | 23.09% | 13.34% | 0.55 | 17.59 | — | — | 0.81 | 47.00% | 699.00% | -1288.00% | 2.95% | — | 16.39% | 0.00% | 0.00% | 3.13% | 21.39 | 35.39 | 6.04 | 6.02 |
| ZBH | Zimmer Biomet Holdings, I… | $98.44 | 19.51B | +4% | -60% | -82% | -46% | 27.93 | 1.55 | 2.39 | 12.01 | — | -10.06 | 61.62% | 16.55% | 8.57% | 5.60% | 6.12% | 3.17% | 0.59 | 4.65 | 1.98 | 0.89 | 3.12 | -1986.00% | 720.00% | 2887.00% | 7.47% | 0.66 | 7.80% | 0.97% | 27.00% | 3.44% | 19.55 | 18.08 | 3.23 | 1.82 |
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
- CEO
- Eric Green
- Employees
- 10.6K
- Beta
- 1.19
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($108.37 ÷ $300.68) − 1 = -63.96% (DCF, example).